Aggrastat, located in Princeton, NJ, is a leading pharmaceutical company that specializes in the development and production of medications for thrombotic cardiovascular events. With over 20 years of clinical research and approval of its first indication in 1998, Aggrastat has become the most widely used GPI (glycoprotein IIb/IIIa inhibitor) in the United States and worldwide, having been utilized in over 400,000 patients since 2013. Aggrastat offers a range of treatment options for patients with different profiles, including those with NSTE-ACS (non-ST segment elevation acute coronary syndrome) who have not been adequately pretreated, patients with renal impairment, and high-risk cases. Their medications, such as the single bolus and maintenance infusion of Aggrastat, are designed to effectively navigate thrombotic cardiovascular events and provide relief to patients in need.Generated from the website

Koamtac

Global Business Supplies

Lexmark

2 Life Entertainment